MBX — MBX Biosciences Balance Sheet
0.000.00%
Annual balance sheet for MBX Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 42.5 | 80.7 | 262 | 374 |
| Net Total Receivables | 0.142 | 0.208 | 0.682 | 2.12 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 44.2 | 83.5 | 267 | 382 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.842 | 0.665 | 1.2 | 3.22 |
| Other Long Term Assets | ||||
| Total Assets | 45.1 | 84.2 | 269 | 385 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 3.43 | 3.93 | 11.1 | 15.5 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 3.82 | 4.29 | 11.1 | 15.9 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 41.3 | 79.9 | 257 | 369 |
| Total Liabilities & Shareholders' Equity | 45.1 | 84.2 | 269 | 385 |
| Total Common Shares Outstanding |